Status:

COMPLETED

Does Weight Loss Surgery and Probiotic Supplementation Lead to a "Lean" Gut Microbiota?

Lead Sponsor:

Tufts Medical Center

Conditions:

Obesity

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

The purpose of the weight-loss study is to characterize the effect of LGG supplementation on the relative abundance of phyla in the gut microbiota of patients undergoing gastric bypass and sleeve gast...

Eligibility Criteria

Inclusion

  • Age greater than or equal to 18 years
  • Able to give informed consent and report on side effects
  • Tolerating an oral/enteral diet
  • Stable comorbid conditions
  • Outpatient

Exclusion

  • Inpatients
  • Pregnancy (urine test done on all patients routinely pre-op)/ unwilling to comply with contraceptive requirement after gastric bypass surgery
  • Known use of LGG or another probiotic (not including yogurt) within the previous 30 days
  • Presence of an active bowel leak, acute abdomen, active intestinal disease, or significant bowel dysfunction
  • Presence of an absolute neutrophil count less than 500 per cubic mm (must have had a Complete Blood Count within the last 6 months) or anticipation post chemotherapy that the absolute neutrophil count will fall below 500 per cubic mm.
  • History of adverse reaction to product containing lactobacillus
  • Active colitis (\*see definition below)
  • Known or suspected allergies to probiotics, lactobacillus, milk protein, or microcrystalline cellulose
  • Structural heart disease, history of endocarditis or valve replacement, implanted cardiac device, congestive heart failure
  • Positive baseline stool culture for LGG
  • Recent or planned chemotherapy or radiation therapy
  • Solid organ transplant within the prior year
  • Stem cell transplant within the prior year
  • On active immunosuppressive medication \[anti-rejection, injectable immunosuppressive drugs for autoimmune disease, or corticosteroids (greater than ½ mg per kg body weight of prednisone or its equivalent) not including inhaled or topical steroids\]
  • Allergy or intolerance to or contraindication to two or more of the rescue antibiotic regimens (ampicillin, clindamycin, moxifloxacin)
  • Participating in another clinical trial
  • Uncontrolled psychiatric illness

Key Trial Info

Start Date :

September 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2016

Estimated Enrollment :

18 Patients enrolled

Trial Details

Trial ID

NCT01870544

Start Date

September 1 2013

End Date

January 1 2016

Last Update

February 10 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Tufts Medical Center Weight and Wellness Center

Boston, Massachusetts, United States, 02111